

Special Issue

Clinical Trials for T-Cell Lymphoma

Message from the Guest Editor

This Special Issue is dedicated to key aspects of the most promising novel therapies in the treatment of T cell lymphomas. From bench to bedside, the focus will be on understanding the mechanisms of action and resistance of these agents and how best to tailor their use in the different subtypes. The key clinical aspects of clinical trials will be highlighted and critiqued for a better understanding of the application of this data. Finally, there will be a discussion on how the paradigm of “one treatment fits all” is changing towards a more molecularly defined approach for treating T cell lymphomas.

Guest Editor

Prof. Dr. Jasmine M. Zain
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

Deadline for manuscript submissions

31 August 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/264283

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)